Literature DB >> 35604455

Prevalence of scoliosis and impaired pulmonary function in patients with type III osteogenesis imperfecta.

M C Keuning1, S J G Leeuwerke2, P R van Dijk3, A G J Harsevoort4, H P Grotjohan5, A A M Franken6, G J M Janus4.   

Abstract

PURPOSE: Osteogenesis Imperfecta (OI) is a rare group of congenital genetic disorders that consists of a collagen synthesis defect. The most severe phenotype is type III OI. Characterized by progressive bone deformity, fragility and pulmonary impairment, causing significant morbidity and mortality. Also, multilevel spine deformities are observed, such as scoliosis. The literature on the pathophysiology of pulmonary impairment in relation to scoliosis in these patients is scarce and conflicting. This study aims to determine the prevalence of scoliosis and its relation to pulmonary function in type III OI patients.
METHODS: This retrospective cohort study took place between April 2020 and November 2021. Forty-two patients with type III OI were included. Anterior-posterior spine radiographs were evaluated for scoliosis. Pulmonary function was assessed using spirometry and partial pressure of carbon dioxide.
RESULTS: All 42 patients had scoliosis, with a mean curve of 66° (95% CI of range). Vital lung capacity was decreased, compared to a non-OI population (mean 1.57 L). This was correlated to the degree of scoliosis (st. β - 0.40, P = 0.03), especially in increasing thoracic curves. Restrictive lung pathophysiology was shown in our study population with a mean FEV1/FVC ratio of 0.85.
CONCLUSIONS: Increasing thoracic scoliosis was correlated with decreased vital lung capacity in our study population of type III OI patients. High FEV1/FVC ratios found in this study population show restrictive lung pathophysiology. Therefore, it is plausible that the pulmonary impairment found in type III OI patients is a combined issue, partly associated to scoliosis and partly intrinsic to OI.
© 2022. The Author(s).

Entities:  

Keywords:  Osteogenesis imperfecta; Pulmonary function; Scoliosis

Mesh:

Year:  2022        PMID: 35604455     DOI: 10.1007/s00586-022-07260-5

Source DB:  PubMed          Journal:  Eur Spine J        ISSN: 0940-6719            Impact factor:   2.721


  19 in total

1.  Cardiovascular abnormalities in adults with osteogenesis imperfecta.

Authors:  Zoran Radunovic; Lena L Wekre; Lien M Diep; Kjetil Steine
Journal:  Am Heart J       Date:  2010-12-24       Impact factor: 4.749

2.  Osteogenesis imperfecta type III. Delineation of the phenotype with reference to genetic heterogeneity.

Authors:  D O Sillence; K K Barlow; W G Cole; S Dietrich; A P Garber; D L Rimoin
Journal:  Am J Med Genet       Date:  1986-03

3.  Causes of death in osteogenesis imperfecta.

Authors:  S J McAllion; C R Paterson
Journal:  J Clin Pathol       Date:  1996-08       Impact factor: 3.411

4.  Operative treatment of severe scoliosis in osteogenesis imperfecta: results of 20 patients after halo traction and posterior spondylodesis with instrumentation.

Authors:  G J Janus; G Finidori; R H Engelbert; M Pouliquen; J E Pruijs
Journal:  Eur Spine J       Date:  2000-12       Impact factor: 3.134

5.  Genetic heterogeneity in osteogenesis imperfecta.

Authors:  D O Sillence; A Senn; D M Danks
Journal:  J Med Genet       Date:  1979-04       Impact factor: 6.318

6.  Osteogenesis imperfecta.

Authors:  J M Gertner; L Root
Journal:  Orthop Clin North Am       Date:  1990-01       Impact factor: 2.472

Review 7.  Osteogenesis imperfecta.

Authors:  Frank Rauch; Francis H Glorieux
Journal:  Lancet       Date:  2004-04-24       Impact factor: 79.321

8.  Rib cage deformities alter respiratory muscle action and chest wall function in patients with severe osteogenesis imperfecta.

Authors:  Antonella LoMauro; Simona Pochintesta; Marianna Romei; Maria Grazia D'Angelo; Antonio Pedotti; Anna Carla Turconi; Andrea Aliverti
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

Review 9.  Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment.

Authors:  F S Van Dijk; D O Sillence
Journal:  Am J Med Genet A       Date:  2014-04-08       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.